Anzeige
Mehr »
Samstag, 13.06.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWFZ | ISIN: US7530181004 | Ticker-Symbol:
NASDAQ
12.06.26 | 21:59
0,760 US-Dollar
+0,01 % +0,000
1-Jahres-Chart
RANI THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
RANI THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur RANI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Rani Therapeutics Holdings, Inc. - 8-K, Current Report2
26.05.Rani Therapeutics raises $20 million in direct offering6
26.05.Rani Therapeutics to raise $20M in registered direct offering5
26.05.Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules2
15.05.Rani Therapeutics CFO Sanford to depart2
15.05.Rani Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.7M beats by $1.2M1
15.05.Rani Therapeutics CFO to depart, reports Q1 results1
15.05.Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition561- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen - - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer...
► Artikel lesen
RANI THERAPEUTICS Aktie jetzt für 0€ handeln
15.05.Rani Therapeutics Holdings, Inc. - 8-K, Current Report2
09.04.Rani Therapeutics appoints Sara Kenkare-Mitra as advisor2
09.04.Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy227SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery...
► Artikel lesen
26.03.Rani Therapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
26.03.Rani Therapeutics Holdings, Inc. - 10-K, Annual Report1
26.03.Rani Therapeutics GAAP EPS of -$0.07 in-line, revenue of $1.46M misses by $3.54M1
25.03.Rani Therapeutics names Jesper Høiland as head of strategy3
25.03.Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization685SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery...
► Artikel lesen
19.03.Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results2
28.01.Rani Therapeutics promotes Alireza Javadi to chief technical officer2
28.01.Rani Therapeutics befördert Alireza Javadi zum Chief Technical Officer13
28.01.Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer273SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1